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Abstract: The most relevant and recent literature findings linking exposure to sunlight, Vitamin D (VD), inflammation and immune
system in health and disease, are reviewed.
Reduced sunlight exposure determined hypo-vitaminosis D to be common among patients or even healthy subjects, especially at
higher latitudes. Numerous studies support the hypothesis that VD insufficiency could contribute to the higher autoimmune diseases
incidence in the same geographic areas.
In the present review, the ways in which VD was reported to influence immune system, contributing to organism homeostasis or
disease development are addressed. In fact, some of the hormone activities were recognised to determine stimulation or inhibition of
immune system components.
Several diseases, where an association with VD deficiency was studied, are summarised. Finally, the rationale for optimization of
substitutive/additive therapy with VD analogues and the last innovations regarding these drugs are mentioned.
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1. INTRODUCTION
Vitamin  D3  (VD3)  is  a  steroidal  hormone,  synthesized  mainly  in  the  skin  from  7-dehydrocholesterol  through
ultraviolet  B  (UVB)  radiation,  and  in  smaller  percentage  provided  by  the  diet.  Further  metabolic  passages  include
conversion  in  the  liver  to  25-hydroxyVD3 (25(OH)D3),  its  circulating  form,  and activation  to  1,25-dihydroxyVD3
(1,25(OH)2D3) by the 1-α-hydroxylase enzyme, in kidney proximal tubule cells [1].
The metabolite measured in blood to establish VD levels is 25(OH)D, being representative of the organism VD
storage [2]. The usual target range for 25(OH)D is 30-60 ng/mL or 75-150 nmol/L [3].
As reported before, cutaneous synthesis provides 80%-100% of VD requirements, but it is to be mentioned that the
natural solar source for starting the metabolic pathway is not equally distributed all over the world [4]. Environmental
factors associated with changing solar zenith angle, such as season, latitude, time of day, determine UVB radiation
strength and its consequent capability of stimulating VD synthesis. In fact, UVB reaches to the earth surface only when
the sun is sufficiently high to penetrate all atmosphere layers. This situation verifies only in the middle of the day and,
beyond the 40th parallel in mid and high latitude regions, only for a few months, from the middle of spring until the end
of  summer.  Therefore,  almost  in  all  Europe  and a  large  portion  of  North  America  and of  the  former  Soviet  Union
countries, exposure to sun includes UVB only during this short time period [5].
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Relevantly, those are the same regions where the highest prevalence of autoimmune diseases is observed.
Likewise,  other  steroidal  hormones,  VD3 appear  to  influence  immune  responses,  in  addition  to  its  well-known
effect on calcium and bone metabolism [6, 7].
Studies performed in the last twenty years of the past century, on patients with granulomatous diseases, such as
sarcoidosis, in which high VD serum levels are present, showed expression of the 25OHD-1-α-hydroxylase enzyme in
granulomas forming macrophages [8]. In fact, conversion of 25-OHD to 1,25(OH)D occurs in immune system cells,
expressing a different form of 1-α-hydroxylase enzyme and capable of converting the precursor to the active form. The
extra-renal enzyme is not regulated by parathyroid hormone, but seems to be induced by cytokines, such as interferon
(IFN)-γ, interleukin (IL)-1, or Tumour Necrosis Factor (TNF)-α [9]. Lately, in sarcoidosis, presence of a high number
of T regulatory cells (Tregs) was demonstrated, together with the peripheral energy of immune system cells [10].
Interestingly,  1-α-hydroxylase  enzyme forms were  also  described in  keratinocytes  and consequently,  they were
considered as a source for autocrine synthesis of 1,25(OH)2D [11].
A pleiotropic  role  for  VD3 is  supported  also  by  the  presence  of  VD Receptor  (VDR)  on  various  cell  types,  in
healthy  and  diseased  tissues  like  bone  marrow,  brain,  colon,  breast,  malignant  and  immune  cells  [12].  In  immune
system cells, VDR is present on monocytes and macrophages, dendritic cells, T cells and B cells. Consequently, it was
postulated that VD can have, in the periphery, a paracrine or autocrine action, binding on responsive elements (VDRE),
located on DNA, and changing the way immune system genes are expressed [13].
Several  studies  testified  the  correlation  between  acquired  VD  deficiency  and  reduced  immune  function  or
autoimmunity  development,  cancer  and  even  cardiovascular  diseases  [14  -  18].
Also, the potential for confounding factors was investigated, since the presence of a systemic inflammatory response
was reported to be associated with lower levels of micronutrients like albumin or lipid soluble vitamins, in plasma [19].
1.1. Vd and Innate Immunity
VD has both stimulatory and inhibitory effects on innate immune cells. Macrophages, monocyte-derived dendritic
cells (DCs) and dermal DCs own the whole enzyme supply needed to convert VD3 into 1,25(OH)2VD3 Figs. (1 and 2)
[20, 21].
Fig. (1). Cell-to cell interactions in immune responses modulated by VD.
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According to in vitro studies, VD could contribute in the induction of differentiation of immature myeloid cells into
monocytes and macrophages [22]. Moreover, VD3 deficiency and hypo-functional VDR polymorphisms are involved in
susceptibility to Mycobacterium tuberculosis and Mycobacterium leprae [23]. Interestingly, studies on Mycobacterium
tuberculosis resistance showed that an important role is exercised by VD in the innate immune system. In fact, VD
seems to be implicated in toll-like receptors (TLRs) dependent pathways, leading to synthesis of bactericidal peptides
like cathelicidin and beta defensin 4, in circulating monocytes and tissue macrophages. Binding of macrophages TLR2
or TLR4 with microbial peptides determines hyper-expression of 1-α-hydroxylase and VDR. The result is the formation
of a heterodimer by 1,25OHD-VDR and retinoid X receptor (RXR) that is able to act over VDRE on cathelicidin and
beta defensin 4 genes, enhancing their transcription. The cited mechanism is determinant for the killing of intracellular
bacteria  [24].  Moreover,  induction  of  superoxide  production  by  THP-1  cells  infected  with  live  Mycobacterium
tuberculosis  and  treated  with  VD3  was  described  [15].
Other studies postulated a VD3 mediated downregulation of TLRs expression on monocytes, of TLRs mediated
innate immune responses and consequently also a limitation of T helper (Th)1 activity [25].
VD is able to suppress the synthesis of IL-12, reduce IFN-α secretion and increase the production of IL-10 by DCs.
Nutritional supplements containing VD determine higher IL-10 blood levels [26, 27]. IL-10 is known to down-regulate
inflammatory responses reducing antigen presentation by DCs and macrophages [28]. DCs are also inhibited in their
differentiation, maturation and immuno-stimulatory function following MHC class II molecules and CD40, CD80 and
CD86 reduced expression [29] (Figs. 1 and 2).
A regulatory function was also reported for VD on leukocyte migration, explained possibly by a reduced peripheral
chemokine synthesis: decreased synthesis of CCL2, CCL3, CXCL10 in Experimental Autoimmune Encephalomyelitis
(EAE) and of CCL2, CCL5, CXCL10 in non-obese diabetic (NOD) mice [30, 31].
Fig. (2). The multiple activities physiologically carried out by VD towards immune system cells are summarized in the figure. In red
all  immuno-regulating,  in  green  all  immuno-stimulating  activities.  IL=  interleukine;  IFN=  interferon;  Th=  T  helper;  Tregs=  T
regulatory.
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1.2. Vd and Adaptive Immunity
Activated T and B cells possess only the enzymatic activity for converting 25(OH)D3 to 1,25(OH)2D3 [32].
VD was correlated with reduced lymphocytes Th1 and Th17 responses and increased Th2 and Tregs activation [33].
Inhibitory effects are especially exercised on memory T cells, in concordance with their higher VDR expression [34]. In
vitro, VD3 inhibits T cell proliferation, IL-2 and IFN-γ secretion and CD8 T cell cytotoxicity [35, 36].
The decrease IL-2 and IFNγ production is mediated by binding of the VDR–rXr complex to promoters of genes
encoding IL-2 and IFNγ [37, 38]. The effect on Th17 cells was attributed to inhibition of IL-6 and IL-23 production
[39].
CD8+  T  cell  deficiency  characterizes  many  autoimmune  diseases.  An  interesting  hypothesis  on  autoimmune
diseases development was proposed in 2012. The Authors postulated that VD lower levels at higher latitudes could
facilitate the development of auto-reactive B cells, by aggravating a deficient control of Epstein Barr virus infection
from CD8 T cells [40].
VD  has  also  inhibitory  effects  on  B  cells  and  plasma-cells,  reducing  their  proliferation,  differentiation  and  Ig
secretion.  In  B  cells,  VDR  receptor  activated  signal  cascade  leads  to  impaired  class  switch  recombination,  with
following reduced IgE synthesis. Up-regulation of IL-10 production in DCs can contribute to this process, inhibiting
IL-4 mediated IgE synthesis [41]. Interestingly, it was demonstrated that cultures of activated B lymphocytes produce
calcitriol and express IL-10 in response to autocrine and exogenous calcitriol production (Figs. 1 and 2). The relevant
immuno-modulatory role of B cells, through production of IL-10, was demonstrated in ulcerative colitis treated with
anti-CD20 (Rituximab). Mucosal B cell reduction and following fall of local IL-10 levels led to higher disease activity
after treatment [42]. Expression of 1-α hydroxylase in B cells seems to be dependent on T cell help, through stimulation
with CD-40 and IL-4 [43].
Also, VD substitutive therapy is reported to reduce Th1 and Th17 and increase Tregs responses. Consequently, also
an  indirect  effect  on  differentiation,  proliferation  and  antibody  production  could  be  postulated  for  B  cells  during
treatment with VD analogues [30, 44].
2. HYPOVITAMINOSIS D AND AUTOIMMUNE DISEASES
From the clinical point of view, hypo-vitaminosis D was associated with higher risk of auto-immune rheumatic
diseases, especially for Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc),
Idiopathic Inflammatory Myopathies (IIM), but also Multiple Sclerosis (MS), Inflammatory Bowel Diseases (IBD),
type 1 diabetes and other autoimmune endocrine diseases [45 - 51].
Interestingly, VD deficiency was associated with an increased autoimmune response also in healthy individuals. In
these subjects, it was demonstrated that VD deficiency was associated with increased auto-immune response with Anti-
Nuclear Antibody (ANA) positivity and higher interferton (IFN)-α activity [43].
It is to be cited that also VDR mutations with reduced function were reported in several autoimmune diseases [26,
52].
Many studies  on  animal  models  attest  the  usefulness  of  supplementation  with  VDR agonists  in  prevention  and
treatment of arthritis, autoimmune diabetes, EAE, IBDs, psoriasis and SLE [53 - 59].
Interestingly,  Sainaghi  et  al.  demonstrated,  in  a  large  retrospective  study,  on  patients  affected  by  autoimmune
rheumatic  diseases,  a  greater  trend  to  development  of  higher  parathyroid  hormone  (PTH)  responses,  compared  to
unaffected subjects with similarly low VD levels. In the study, the Authors observed that VD plasmatic concentrations,
age  and  an  autoimmune  rheumatic  disease,  were  independent  predictors  for  hyperparathyroidism.  Therefore,  a
hypothesis for an impairment of VD metabolism in course of inflammation has been developed, characterized by a
scarce  suppressive  activity  of  VD on PTH secretion.  Consequently,  the  research concludes  that  VD concentrations
should always be assessed together with that of PTH, calcium and phosphate, to evaluate VD metabolism correctly.
Moreover, the Authors postulate that VD supplementation should, therefore, be targeted to obtain PTH suppression [60]
A following study from the same group, demonstrated in autoimmune rheumatic diseases affected patients, that a
treatment with a single oral dose of cholecalciferol 300,000 IU, followed by oral cholecalciferol 800-1000 IU daily for
6 months, was a more effective regime for determining PTH suppression [61].
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2.1. Systemic Lupus Erythematosus
Many  clinical  studies  focused  on  the  relation  between  hypo-vitaminosis  D  and  SLE  [62].  SLE  patients  are  by
definition VD deficient, because instructed on sun avoidance and use of sunscreens [43, 63].
Some authors studied the seasonality of disease flares, showing that SLE reactivation was correlated with lower VD
serum levels, in wintertime [64].
A  meta-analysis  of  eleven  heterogeneous  articles  showed  in  most  of  the  papers  an  inverse  correlation  between
serum VD levels and SLE disease activity [65].
Regarding  organ  specific  aspects,  an  association  was  found  by  several  studies  between  VD  levels,  general
cardiovascular  risk,  vascular  stiffness  and  endothelial  dysfunction,  in  SLE  patients  [66,  67].  Moreover,  hypo-
vitaminosis  D  was  also  associated  with  SLE  with  cognitive  impairment,  fatigue  and  sleep  disorders  [68,  69].
In  SLE patients,  several  prospective  studies  (each  with  a  different  treatment  schedule)  were  performed  on  VD
supplementation, with contrasting results. Terrier et al. described an increase in naive T CD4+ and regulatory T cells
and a decrease in Th1, Th17 and B memory cells numbers [70].
Andreoli et al.  described higher levels of Tregs cells and Th2 cytokines after long term monthly treatment with
cholecalciferol [71].
An intensive regimen of VD supplementation in SLE patients with inactive disease, showed to obtain sufficient
levels of serum 25(OH)D, but no effect on disease activity or serology [72].
On the other hand, Aranow et al. described failure of a VD supplementation, up to 4,000 IU daily, in diminishing
the  IFN  signature  in  VD-deficient  SLE  patients  in  a  12-week  double-blind,  placebo-controlled  trial.  The  Authors
hypothesized that higher VD levels sustained for a longer period may be required to affect immunologic outcomes [73].
Polymorphisms  of  VDR  seem  to  account  for  the  individual  response  to  VD,  and  it  was  found  that  some  are
associated with increased risk of SLE development and to disease phenotype [74, 75].
2.2. Rheumatoid Arthritis
Multicentre studies have shown significantly lower 25(OH)D serum levels in RA patients compared to matched
controls [76]. It was recently demonstrated that VD serum concentrations appear to correlate with clinimetric indexes
for quality of life, disease activity and disability in a cohort of RA European patients [77, 78]. The Authors constructed
a  new  Patient  Reported  Outcome  (PRO)  questionnaire  for  RA  patients’  self-estimation  of  the  risk  for  VD
insufficiency/deficiency-related  clinical  implications  (D-PRO)  [70].
Many studies have linked a higher risk of RA development to higher latitudes especially in winter months [79].
Lower UV-B light exposure was extensively studied as a risk factor for RA development in prospective cohort studies,
the Nurses’ Health Study (NHS) and the NHSII, confirming a significantly decreased risk with higher UVB exposure
especially in the absence of sun-protective behaviours [80].
It was also demonstrated in RA that winter or spring season of symptom onset can act as an independent predictive
factor for joint structural damage progression at 6 months and radiographic progression at 12 months [81].
Presence  of  severe  25(OH)D  deficiency  (<10 ng/ml)  was  associated  with  worsening  of  symptoms  like
musculoskeletal  pain  in  RA,  while  improvements  are  seen  after  supplementation  [82,  83].  Pre-treatment  of  human
macrophages  with  oestrogens  can  reproduce  the  hormonal  milieu  of  the  inflamed  RA  joints,  where  aromatase  is
activated  and  pro-inflammatory  cytokines  are  released.  It  was  demonstrated  that  VD  treatment  blocks  completely
oestrogen related aromatase activation [84, 85].
2.3. Systemic Sclerosis
In  SSc  patients,  low  VD  serum  concentrations  have  been  shown  [86].  Arnson  et  al.  demonstrated,  in  a  large
multinational SSc patients’ population, that lower serum VD concentrations were inversely correlated with the extent of
cutaneous fibrosis [87].
A  correlation  with  severe  nailfold  video-capillaroscopic  alterations  and  worse  quality  of  life  parameters  were
reported in patients with diffuse SSc form and with lower 25(OH)D serum concentrations [88].
Moreover, in a large study on SSc patients from two European reference centres, serum 25(OH)D deficiency was
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found to correlate with severe lung involvement, peripheral vascular, kidney and gastrointestinal Medsger’s disease
severity scale parameters.  Furthermore,  25(OH)D serum levels  were reported to correlate  with seasonality,  while  a
supplementation with standard doses of oral cholecalciferol was found not effective in normalising serum 25(OH)D
values [89, 90].
2.4. Idiopathic Inflammatory Myopathies
VD deficiency was reported in patients with Idiopathic Inflammatory Myopathies (IIM) like Polymyositis (PM),
Dermatomyositis (DM), Inclusion Body Myositis (IBM) compared to controls matched for age, gender and month of
serum sampling. VD levels were found to be lower in patients more close to diagnosis than in those with established
disease, suggesting that low levels of VD may constitute a risk factor for developing IIM. As for RA, the IIM cases
were found to be diagnosed more frequently during winter or spring. Finally, higher serum anti-Jo-1 antibodies title
were shown to be correlated with lower serum 25(OH)D levels [49].
2.5. Multiple Sclerosis
Multiple studies strongly suggested that an insufficient exposure to sun or VD assumption, during the first part of
life, constitutes a major risk for MS development [91, 92].
Supplementation with VD has shown to have multiple positive immunological effects in patients affected by MS.
Higher Tregs count, IL-10 cytokine activity and reduction of the pro-inflammatory Th17 lymphocytes, of IL-17 and of
B-cell immunoreactivity were achieved [93 - 95]. Additionally, low serum 25 (OH)D and a recent Epstein-Barr Virus
(EBV) infection were found to be associated with blood donors with the first clinical MS manifestation [96 - 97].
3. VD SUBSTITUTIVE/ADDITIVE THERAPY
A recent consensus conference confirmed the necessity of VD and calcium supplementation in patients on therapy
with steroids or other drugs that may reduce bone mineral density. 25OHD levels are considered to be measured once a
year and replaced in those patients with insufficient/deficient levels [98, 99].
A Cochrane Review in 2014 stated that VD3 seemed to decrease mortality in elderly people living independently or
in institutional care, while VD2, alfacalcidol and calcitriol had no statistically significant beneficial effects on mortality
[100].
The existence of a synergism between VD3 and glucocorticoids was demonstrated: when VD3 is assumed combined
with dexamethasone, there seems to be significant additive effects on inhibition of lymphocyte proliferation and Th1
cytokine production [101].
Moreover, it was demonstrated, even in healthy subjects, that VD supplementation (140,000 IU at baseline and after
4 weeks) seems to determine significant increase of Tregs percentage, suggesting a possible use of VD as additional
therapy in autoimmune diseases [102, 103].
Different results of in vitro and animal models studies on VD supplementation, compared to studies performed on
humans, may be justified by the fact that, while in the first two cases the active form of the molecule is used, in the
second most of the times the precursor activity is evaluated. This difference determines the existence of a phase of the
study where the quantitative and qualitative characteristics of the molecule activity are poorly controllable. Part of such
variability may be due to the individual VDR receptor polymorphisms and/or to epigenetic changes.
However, peripheral conversion of pro-VD in calcitriol sustain the use of the first as a therapeutic agent, being a
storage molecule with longer half-life and reduced hypercalcaemic effect [16].
A link between inflammation and neoplastic transformation is increasingly supported by recent literature and VD
anti-proliferative actions suggested its possible use also in different types of cancers [104, 105]. VD3 showed anti-
melanoma activity in experimental models, and defects in VD signalling seemed to contribute to tumour progression
and disease outcome [106]. Studies on animal models of breast cancer have shown several tumour suppressive actions
of VDR agonists, while human VD deficiency is common in breast cancer patients and low VD status was reported to
enhance the risk for neoplasms development or progression [107]. VD/VDR deficiency was reported also in prostate
cancer patients together with higher C reactive protein and IL-8 levels, providing evidence for an association among
prostate cancer, VD deficiency and inflammation [108].
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CONCLUSION
In  conclusion,  from  available  literature  it  can  be  observed  clearly  that  VD  is  a  determinant  factor  for
immunomodulation. It has to be said that inflammatory reactions could ‘consume’ VD in autoimmune diseases, and
hypovitaminosis  could  be  a  consequence.  However,  this  would  not  be  coherent  with  the  results  of  genetic  studies
specifically linking genotypes regulating VD metabolism to higher autoimmunity susceptibility and with the findings of
the numerous epidemiological studies cited [109]. Moreover, the beneficial effects of VD supplementation, observed in
several conditions, further testify for a major role of VD in immuno-modulation [110].
The increasing interest for VD and VDR in bone biology, metabolic diseases, immunological disorders and cancer,
took pharmaceutical companies to develop over more than 3,000 VD analogues in the last 30 years.
Next studies will probably continue to concentrate on new direct VDR agonists with a better biological profile for
applications in therapy. Knowledge of structures of the VDR ligand-binding domain and its ligands will lead to the
creation of VDR agonists with increased affinity for VDR receptor and augmented molecular metabolic stability.
As a consequence, a higher preventive and therapeutic potential, also for extra-skeletal chronic diseases, such as
autoimmune and cardiovascular diseases, cancer, diabetes and infections, will be obtained.
DCs= dendritic cells; Th= T CD4+ helper cell subsets (Th1, Th2, Th3-Treg, Th17) originating from naïve T cell
(Th0). Thin arrows (left) indicate cytokines that induce differentiation of Th0 cells and thicker arrows (right) indicate
cytokines produced by activated Th cell subsets. B cells and Natural Killer T cells (NKT) are also reported.
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